In low- and middle-income countries, diagnostic pathways for inherited hemoglobin disorders frequently break down between initial population screening and final medical care, leaving at-risk families without actionable clinical guidance. A narrative evidence synthesis published in Frontiers in Genetics by Savitri M. Nerune and Sayandeep K. Das of the Shri B. M. Patil Medical College Hospital and Research Centre in Karnataka, India, demonstrates that expanding laboratory hardware alone cannot resolve the burden of hemoglobinopathies. Integrating regional evidence from India, Ghana, Bangladesh, Sri Lanka, Thailand, and Indonesia, the review establishes that diagnostic completion requires bridging systemic handoffs between primary hematological screening, phenotypic resolution, and selective molecular confirmation. Rather than recommending universal genetic sequencing, which remains unfeasible across resource-constrained settings, the authors show that reliable disease prevention hinges on addressing severe attrition occurring after screen-positive results are identified.
The operational realities in India illustrate how health-system fragmentation disrupts patient tracking and clinical follow-up. Indian national guidance distributes carrier confirmation to district laboratories while reserving advanced deoxyribonucleic acid analysis and prenatal diagnosis for regional and tertiary centers, rendering referral unavoidable when specialized testing is locally absent. In an antenatal screening study across 36 districts in five Indian states, clinicians screened 33,270 pregnant women and identified 2,268 carriers, reflecting a 6.8 percent positivity rate. Although 86.4 percent of corresponding male partners completed testing, only 246 of the 339 couples identified as high risk finalized fetal testing, revealing a 27.4 percent attrition rate. Even within an eighty-seven-clinic network using cold-chain couriers and digital dashboards at an approximate cost of 550 Indian rupees per enrolled family, four percent of women could not complete testing due to sample loss, labeling errors, deterioration, and paternal migration.
Diagnostic pathways across the Indian subcontinent must also navigate extreme geographic heterogeneity in hemoglobin variants, which complicates standard automated screening thresholds. Variant distributions exhibit distinct regional concentrations: hemoglobin E is concentrated across eastern and northeastern states, hemoglobin S predominates across central, western, eastern, and southern tribal belts, hemoglobin D-Punjab appears in northwestern populations, and beta-thalassemia is distributed across diverse communities nationwide. State-level carrier rates within the multicenter antenatal program ranged from 2.9 percent to 11.0 percent, creating disparate diagnostic challenges across different jurisdictions. Because carrier states, compound heterozygosity, and co-inherited modifier alleles can generate deceptively similar hematological indices, automated instrument classification often yields ambiguous readings. In an observational analysis of 1,900 patient samples from Gujarat, automated analyzer windows repeatedly proved insufficient for definitive categorization, necessitating comprehensive correlation with red blood cell indices and family pedigree data to differentiate complex hemoglobin patterns from benign baseline traits.
In Ghana, reference laboratory records documented the screening of 528,735 newborns between 1995 and 2020 using dried blood spots and isoelectric focusing, identifying 9,068 sickle cell disease cases, an overall yield of 1.71 percent. However, funding constraints restricted routine geographic coverage primarily to the Ashanti region until fourteen additional collection sites were added in 2020. At Korle Bu Teaching Hospital, baseline workflows initially captured only 4,427 of 9,990 eligible newborn deliveries, or 44.3 percent, detecting 79 presumptive cases before procedural redesign elevated coverage to 83.7 percent. Despite these improvements, supply shortages and result delays persisted, while an independent evaluation of 354 sickle cell patients revealed that only 44 percent achieved formal diagnosis by four years of age, with 66 percent diagnosed during an acute pain crisis.
In a nationwide survey of 1,877 individuals across Bangladesh, abnormal beta-globin gene carrier frequency reached 11.89 percent, comprising 8.68 percent hemoglobin E trait and 2.24 percent beta-thalassemia trait, with divisional prevalence ranging from 4.2 percent in Khulna to 27.1 percent in Rangpur. Carrier frequency reached 23.5 percent among participants with consanguineous parents compared to 11.4 percent among non-consanguineous participants, while 62.3 percent of respondents lacked prior knowledge regarding disease etiology. In Sri Lanka, an evaluation of 1,774 patients across 23 centers identified homozygous beta-thalassemia in 68.7 percent and hemoglobin E beta-thalassemia in 20.3 percent, with 45 to 55 new births recorded annually without a nineteen-year decline. Meanwhile, a Thai cohort screening 18,976 pregnancies documented 12,499 screen-positive mothers, yet 46.4 percent of eligible male partners remained unscreened, showing that sequential maternal-first testing designs frequently collapse before reproductive risks can be determined.
Targeted cascade screening among relatives of diagnosed index patients offers a high-yield entry point when universal screening is absent. In West Java, Indonesia, an extended family screening study evaluated 150 relatives of known index patients alongside 151 control-family relatives, detecting carriers in 42.7 percent of index relatives compared to 10.6 percent among controls. A separate meta-analysis synthesized 29 epidemiological studies encompassing 83,674 participants across Southeast Asia, establishing a pooled regional alpha-thalassemia prevalence of 22.6 percent, with country estimates reaching 51.5 percent in Vietnam, 39.5 percent in Cambodia, 26.8 percent in Laos, 20.1 percent in Thailand, and 17.3 percent in Malaysia amid statistical heterogeneity exceeding 99.5 percent. Because cis alpha-zero deletions can cause fatal hemoglobin Bart hydrops fetalis, protein-based techniques often fail to detect silent deletion carriers, demonstrating that uniform national screening rules cannot accommodate regional genetic diversity without selective molecular verification.
First-line hematological screening remains an essential public health tool because it provides an accessible entry point into clinical pathways. Routine complete blood counts measuring mean corpuscular volume, mean corpuscular hemoglobin, red blood cell count, and red cell distribution width promptly identify microcytosis, but these parameters frequently overlap with widespread iron deficiency anemia, especially in pregnant women and young children. Discriminant mathematical formulae can assist clinical triage, but their diagnostic accuracy fluctuates across analyzer platforms, patient age cohorts, inflammatory states, and underlying variant spectra. Adjunctive modalities such as osmotic fragility testing, dichlorophenolindophenol assays, and sickle solubility tests can expand peripheral screening access. However, the authors caution that screening rules must never function as exclusion criteria, because structural variant carriers may exhibit normal red blood cell indices, and silent alpha- or beta-thalassemia alleles frequently escape conventional hematological cut-offs.
Definitive phenotypic resolution depends on cation-exchange high-performance liquid chromatography and capillary electrophoresis as complementary fractionation platforms. While high-performance liquid chromatography quantifies major fractions, capillary electrophoresis resolves co-elution, and isoelectric focusing provides essential separation for newborn screening. Nevertheless, analyzer retention windows represent analytical migration zones rather than absolute molecular identities. Diagnostic ambiguity frequently arises in borderline hemoglobin A2 measurements, which can be altered by silent beta-globin mutations, co-inherited alpha- or delta-thalassemia, pregnancy, iron deficiency, platform bias, or co-eluting variants. In an Indian cohort examining 205 borderline cases, researchers uncovered identifiable genetic or acquired causes in 168 patients, noting that confirmed beta-thalassemia carriers occasionally presented with hemoglobin A2 below 3.5 percent and mean corpuscular volumes exceeding 80 femtoliters. The review advocates creating an indeterminate category on laboratory reports to prompt immediate secondary testing rather than forcing unverified classifications.
Selective molecular analysis provides the capstone for resolving ambiguous phenotypes, but it cannot compensate for flawed sample collection or uncritical interpretation of chromatography windows. Molecular referral is clinically justified when microcytosis persists despite corrected iron stores, when hemoglobin A2 values are borderline in couples contemplating reproduction, or when automated findings disagree with clinical severity. Available technologies must align with suspected regional lesions, utilizing allele-specific polymerase chain reaction, reverse dot blot hybridization, or amplification refractory mutation system assays for prevalent point mutations, gap-polymerase chain reaction for frequent alpha-globin deletions, and multiplex ligation-dependent probe amplification for copy-number variants. Although targeted next-generation sequencing can clarify elusive variants, high sequence homology between HBA1 and HBA2 genes, testing costs, bioinformatic demands, and variants of uncertain significance limit its standalone utility. Consequently, the authors conclude that updating regional mutation panels delivers greater diagnostic efficiency than deploying broad sequencing.
The persistent failure to complete diagnostic pathways stems from cumulative out-of-pocket costs and organizational bottlenecks rather than purely technological deficits. Beyond paying direct laboratory fees for complete blood counts, chromatography, or genetic assays, families incur indirect expenses for intercity transit, repeat phlebotomy, lost wages, accommodation, and partner testing. Even where instruments are present, low-volume rural centers frequently lack regular calibration, reagent supplies, external quality assessment, and specialized interpretive staff. Furthermore, laboratory findings deliver minimal preventive value if carrier results are not communicated through culturally sensitive, local-language genetic counseling that includes pedigree construction and active partner engagement. While national initiatives like India’s National Sickle Cell Anaemia Elimination Mission, Malaysia’s Form 4 adolescent screening program, and Iran’s premarital screening framework aim to detect carriers earlier, their success depends on preserving informed voluntary consent, strict confidentiality, and reproductive autonomy across vulnerable populations.
To eliminate the diagnostic completion gap, the authors outline an actionable three-level health architecture paired with measurable accountability metrics across low-resource settings. Level 1 centers at district facilities capture three-generation family histories, complete blood counts, and low-cost point-of-care screening. Level 2 centers perform high-performance liquid chromatography, capillary electrophoresis, and orthogonal phenotyping supported by standardized reports detailing analytical limitations. Level 3 regional hubs provide targeted molecular platforms, including gap-polymerase chain reaction and sequencing panels for resolving complex genotypes and confirming parental mutations prior to prenatal testing. To monitor performance, the authors introduce the diagnostic completion proportion, calculated as screen-positive patients who receive an actionable interpretation, documented counseling, and an appropriate clinical referral divided by total positive screens. Shifting institutional focus from crude screening totals to verifiable diagnostic completion offers a practical roadmap to transform initial screening into enduring care.
Subject of Research: Hemoglobinopathy diagnostic pathways and completion bottlenecks in low- and middle-income countries
Article Title: Hemoglobinopathy diagnosis in LMICs: from hematological screening to molecular confirmation
Article References: Nerune, S. M., & Das, S. K. (2026). Hemoglobinopathy diagnosis in LMICs: from hematological screening to molecular confirmation. Frontiers in Genetics, 17, Article 1969093. https://doi.org/10.3389/fgene.2026.1969093
Image Credits: AI Generated
DOI: 10.3389/fgene.2026.1969093
Keywords: hemoglobinopathies, beta-thalassemia, sickle cell disease, high-performance liquid chromatography, capillary electrophoresis, molecular confirmation, carrier screening, diagnostic completion gap, prenatal diagnosis, genetic counseling, cascade screening, borderline HbA2, alpha-thalassemia, dried blood spot, isoelectric focusing, gap-PCR, India health systems, low- and middle-income countries
News Source: Ophelia Keating. (November 14, 2026). Diagnostic Gaps Hinder Hemoglobinopathy Care Across Developing Nations Review Shows. Scienmag.



